Mark S. Blumenkranz, Director at Avalanche Biotechnologies, Inc. ([AAVL]), sold 22,500 shares at $35.36 ($798K) on 2015-05-15, disclosed to the SEC on 2015-05-18.
Scheduled sale ($798k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.36 | 17,975 | $636K | 79.6% |
| 2 | $36.00 | 4,525 | $163K | 20.4% |
| Total | $35.49 avg | 22,500 | $798K | 100% |
| Filing → |
| [AAVL] | SELL | 2015-06-08 | $200K | — | Filing → |
| AAVL | SELL | 2015-05-21 | $37K | — | Filing → |
| [AAVL] | SELL | 2015-05-13 | $25K | — | Filing → |